Pharmacological Characterization of the Microsomal Prostaglandin E(2) Synthase-1 Inhibitor AF3485 In Vitro and In Vivo

RATIONALE: The development of inhibitors of microsomal prostaglandin (PG)E(2) synthase-1 (mPGES-1) was driven by the promise of attaining antiinflammatory agents with a safe cardiovascular profile because of the possible diversion of the accumulated substrate, PGH(2), towards prostacyclin (PGI(2))....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Di Francesco, Luigia, Bruno, Annalisa, Ricciotti, Emanuela, Tacconelli, Stefania, Dovizio, Melania, Guillem-Llobat, Paloma, Alisi, Maria Alessandra, Garrone, Beatrice, Coletta, Isabella, Mangano, Giorgina, Milanese, Claudio, FitzGerald, Garret A., Patrignani, Paola
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7147323/
https://ncbi.nlm.nih.gov/pubmed/32317963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00374
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados